We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Guidance to help medicine manufacturers meet safe limits on levels of nitrosamine impurities in medicines.
Notification Fees for Great Britain and Northern Ireland
Poster with advice for healthcare professionals on how to carry out point of care testing safely and correctly.
The findings and recommendations of the Expert Advisory Group on paclitaxel drug-coated balloon catheters and drug-eluting stents which are used to treat patients with peripheral arterial disease.
For manufacturers reporting adverse incidents with intraocular lenses under the vigilance system.
Guidance and change control form to request a change to an Advisory Committee on Borderline Substances (ACBS) application form and/or guidance.
The UK government has introduced the Northern Ireland MHRA Authorised Route (NIMAR). This new route for supply became operational 1 January 2022.
Report on the service providing sterile, controlled environments for the preparation of injectable medicines into ready-to-administer formats for patients.
Supplementary information for international regulators on packaging changes and the export of UK medicines.
Patient communication about a very low risk to patient safety in response to the field safety notice (FSN) issued by Diffuplast and MHRA.
The MHRA is ready to provide any assistance for clinical trials applications submitted for COVID-19
VDEC’s Discovery and surveillance capabilities provide unique services across a spectrum of molecular immunology platforms.
Update on MHRA UK risk-based GxP inspection programme.
Information for retailers from Great Britain supplying medical devices to Northern Ireland.
Actions that trial sponsors should consider to build resilience into clinical trial design
VDEC works with global leaders from all sectors to develop and deliver the vaccine and therapeutic products we need to protect us from infectious diseases.
Guidance for specialists for initiation of valproate in female patients and for annual review and pregnancy testing to support adherence to pregnancy prevention requirements during the pandemic.
Information on how the ACBS factors in the issue of pricing, when reviewing product applications.
A set of principles for understanding the impact of new variants on antiviral drugs and monoclonal antibodies
Outcomes from the first meeting with the regulators of medicine who had met globally to discuss dementia.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).